Publication

Intractable ascites associated with mycophenolate in a simultaneous kidney-pancreas transplant patient: a case report.

Journal Paper/Review - Dec 12, 2017

Units
PubMed
Doi
Contact

Citation
Weber N, Sigaroudi A, Ritter A, Boss A, Lehmann K, Goodman D, Farese S, Weiler S, Müller T. Intractable ascites associated with mycophenolate in a simultaneous kidney-pancreas transplant patient: a case report. BMC Nephrol 2017; 18:360.
Type
Journal Paper/Review (English)
Journal
BMC Nephrol 2017; 18
Publication Date
Dec 12, 2017
Issn Electronic
1471-2369
Pages
360
Brief description/objective

Mycophenolic acid (MPA), either given as an ester pro-drug or as an enteric-coated sodium salt, is the most commonly prescribed anti-proliferative immunosuppressive agent used following organ transplantation and widely applied in immune-mediated diseases. Clinicians are well aware of common adverse reactions related to MPA treatment, in particular diarrhea, leukopenia and infections. Here we report a case of severe, persistent ascites associated with MPA treatment. The otherwise unexplained and intractable ascites, requiring repeated paracenteses for more than 8 months, rapidly ceased with stopping the MPA treatment. To our knowledge this is the first case of severe ascites associated with MPA treatment reported in the scientific literature.